Innovation Pipeline

MyndTec’s innovation pipeline features two transformative technologies: MyndLink for optimizing predictive outcomes in Spinal Cord Stimulation (SCS) and a groundbreaking Brain Cell Regeneration therapy.”

MyndLink, currently in the Clinical stage, uses AI to optimize treatment for spinal cord injury by selecting the best patient candidates for spinal cord stimulation. The Brain Cell Regeneration technology, in the Preclinical stage, harnesses the body’s own neural stem cells, guided by electrical stimulation, to repair brain tissue in conditions like Parkinson’s and Alzheimer’s. Together, these innovations position the company to lead in neurological care, offering significant growth potential and the opportunity to improve patient outcomes while advancing healthcare solutions.